FY2029 EPS Estimates for enGene Reduced by Leerink Partnrs

enGene Holdings Inc. (NASDAQ:ENGN - Free Report) - Equities researchers at Leerink Partnrs cut their FY2029 earnings estimates for enGene in a report issued on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now forecasts that the company will earn $0.57 per share for the year, down from their previous estimate of $0.60. The consensus estimate for enGene's current full-year earnings is ($1.57) per share.

enGene (NASDAQ:ENGN - Get Free Report) last issued its quarterly earnings results on Thursday, December 19th. The company reported ($0.34) EPS for the quarter, topping analysts' consensus estimates of ($0.40) by $0.06.

Other research analysts have also issued research reports about the stock. Raymond James started coverage on shares of enGene in a report on Wednesday, November 27th. They set an "outperform" rating and a $23.00 price target for the company. HC Wainwright assumed coverage on shares of enGene in a research note on Monday, December 23rd. They set a "buy" rating and a $25.00 target price for the company. JMP Securities restated a "market outperform" rating and issued a $18.00 target price on shares of enGene in a report on Monday, December 23rd. Finally, Citizens Jmp upgraded enGene to a "strong-buy" rating in a report on Monday, November 18th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, enGene has a consensus rating of "Buy" and an average target price of $29.78.

enGene Trading Down 1.8 %

Shares of ENGN traded down $0.13 during mid-day trading on Thursday, reaching $7.16. 35,738 shares of the company were exchanged, compared to its average volume of 89,356. The business has a 50 day simple moving average of $7.37 and a two-hundred day simple moving average of $7.54. The company has a debt-to-equity ratio of 0.08, a quick ratio of 16.87 and a current ratio of 16.87. The stock has a market capitalization of $316.62 million, a PE ratio of -12.34 and a beta of -0.65. enGene has a 52 week low of $4.42 and a 52 week high of $18.40.

Institutional Trading of enGene

Several large investors have recently made changes to their positions in the company. Wolverine Asset Management LLC bought a new position in shares of enGene in the third quarter valued at $37,000. Point72 Asset Management L.P. raised its holdings in shares of enGene by 1,410.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company's stock worth $4,376,000 after acquiring an additional 619,100 shares during the last quarter. Finally, Franklin Resources Inc. lifted its position in enGene by 48.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company's stock valued at $7,854,000 after acquiring an additional 389,918 shares in the last quarter. 64.16% of the stock is currently owned by institutional investors and hedge funds.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.